Sugi Predict

Sugi Predict / Compounds / SCHEMBL669662

SCHEMBL669662

SCHEMBL669662

CNS(=O)(=O)c1c(OC)cccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ CA2 P00918 5/20 0.43
▸ CA1 P00915 4/20 0.43
▸ ACHE P22303 2/20 0.43
▸ CA12 O43570 2/20 0.42
▸ CA7 P43166 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42
▸ CA4 P22748 1/20 0.42
▸ TNNI3K Q59H18 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HTR6 P50406 1/20 0.40
▸ KAT7 O95251 1/20 0.40
▸ KAT6B Q8WYB5 1/20 0.40
▸ KAT6A Q92794 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371571 0.87 L3MBTL1 (0.42) L3MBTL1CA2CA1CA12CA7
SCHEMBL2371550 0.78 L3MBTL1 (0.61) L3MBTL1CA2CA1CA12CA7
SCHEMBL29965203 0.78 L3MBTL1 (0.61) L3MBTL1CA2CA1CA12CA7
SCHEMBL3555416 0.77 L3MBTL1 (0.51) L3MBTL1CA2CA1ACHECA12
SCHEMBL21360277 0.76 KEAP1 (0.46) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL8907054 0.76 EDNRA (0.57) L3MBTL1LMNAALDH1A1HTTSMN1; SMN2
SCHEMBL25044629 0.76 CA2 (0.48) CA2CA1ACHECA12CA7
SCHEMBL6807395 0.74 CA2 (0.51) CA2CA1ACHECA12CA7
SCHEMBL1500874 0.74 CA2 (0.46) CA2CA1ACHECA12CA7
SCHEMBL669064 0.74 CA2 (0.48) L3MBTL1CA2CA1ACHECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3334713-A1 PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES Memorial Sloan Kettering Cancer Center (US) 2018-06-20 — — EP disclosed
WO-2017027845-A1 PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2017-02-16 — — WO disclosed
WO-2017027841-A1 PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2017-02-16 — — WO disclosed
EP-3129767-A1 REACTIVE LABELLING COMPOUNDS AND USES THEREOF Academia Sinica (TW) 2017-02-15 — — EP disclosed
WO-2015148915-A9 REACTIVE LABELLING COMPOUNDS AND USES THEREOF ACADEMIA SINICA (TW) 2016-12-22 — — WO disclosed
WO-2016100444-A1 TREATMENT OF CLOSED HEAD INJURY AND HEMORRHAGIC STROKE WITH HBED UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-06-23 — — WO disclosed
WO-2016077581-A1 ISOSTEVIOL TRIAZOLES AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-05-19 — — WO disclosed
EP-3003314-A2 NOVEL COMPOUNDS AND USES THEREOF Kala Pharmaceuticals, Inc. (US) 2016-04-13 — — EP disclosed
EP-2970504-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF Sage Therapeutics, Inc. (US) 2016-01-20 — — EP disclosed
WO-2015148915-A1 REACTIVE LABELLING COMPOUNDS AND USES THEREOF ACADEMIA SINICA (TW) 2015-10-01 — — WO disclosed
WO-2014197313-A2 NOVEL COMPOUNDS AND USES THEREOF KALA PHARMACEUTICALS, INC. (US) 2014-12-11 — — WO disclosed
WO-2014160441-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF SAGE THERAPEUTICS, INC. (US) 2014-10-02 — — WO disclosed
US-20140235638-A1 Anti-Infective Agents and Uses Thereof ABBVIE INC. (US) 2014-08-21 — — US disclosed
WO-2013147711-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-10-03 — — WO disclosed
US-8415351-B2 Anti-infective agents and uses thereof ABBOTT LABORATORIES (US) 2013-04-09 — — US disclosed
EP-2512386-A1 A GASTROINTESTINAL IMPLANT DEVICE Vysera Biomedical Limited (IE) 2012-10-24 — — EP disclosed
US-20120213733-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF ABBOTT LABORATORIES (US) 2012-08-23 — — US disclosed
WO-2011073970-A1 A GASTROINTESTINAL IMPLANT DEVICE VYSERA BIOMEDICAL LIMITED (IE) 2011-06-23 — — WO disclosed
US-20110070193-A1 Anti-Infective Agents and Uses Thereof ABBOTT LABORATORIES (US) 2011-03-24 — — US disclosed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070193-A1 Anti-Infective Agents and Uses Thereof MPO, SERPINB1, ELANE L3MBTL1 2449/4885CA2 1429/4885CA1 2881/4885
US-20120213733-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF MPO, SERPINB1, ELANE L3MBTL1 2449/4885CA2 1429/4885CA1 2881/4885
US-20140235638-A1 Anti-Infective Agents and Uses Thereof MPO, ELANE, LPO L3MBTL1 2587/4885CA2 1551/4885CA1 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.